NCT04943211 (HISTIOGEN) is a Phase 3 clinical trial of fluorodeoxyglucose (18F-FDG) in Histiocytosis, sponsored by Anna Raciborska.

Who is sponsoring NCT04943211?

NCT04943211 is sponsored by Anna Raciborska.

What drugs are being tested in NCT04943211?

Interventions in NCT04943211: fluorodeoxyglucose (18F-FDG).

What condition does NCT04943211 study?

NCT04943211 studies Histiocytosis.

Is NCT04943211 still recruiting?

NCT04943211 is currently recruiting now. Last updated 25 March 2026.

Last reviewed 2026-03-25 · How we verify

NCT04943211: HISTIOGEN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Recruiting now Phase 3 Last updated 25 March 2026

What this trial tests

Phase 3 trial testing fluorodeoxyglucose (18F-FDG) in Histiocytosis in 150 participants. Currently enrolling.

Timeline

1 April 2021

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	Anna Raciborska
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	150
Start date	1 April 2021
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	1 location across Poland

Drugs / interventions tested

fluorodeoxyglucose (18F-FDG) — full drug profile →

Conditions studied

Histiocytosis — all drugs for Histiocytosis →

Sponsor

Anna Raciborska — full company profile →

Who can join

Adults 1 to 18, any sex, with Histiocytosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, low intervention, open, single-center, non-commercial clinical trial to improve diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor tissues, monitoring its presence in free-circulating DNA, and determining the efficacy of fluorodeoxyglucose (18F-FDG) in PET-CT imaging.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Histiocytosis

Currently open trials in the same condition.

NCT04943224 — Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients · Phase 2 · recruiting
NCT04943198 — Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis · Phase 2 · recruiting
NCT04665674 — Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study · recruiting

Other Anna Raciborska trials

Trials by the same sponsor.

NCT05968768 — To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) · Phase 2 · recruiting
NCT04943224 — Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients · Phase 2 · recruiting
NCT04943198 — Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04943211 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anna Raciborska
Last refreshed: 25 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing